DE3479398D1 - Immunomodulating medicine based on fc fragments of human igg - Google Patents

Immunomodulating medicine based on fc fragments of human igg

Info

Publication number
DE3479398D1
DE3479398D1 DE8484402531T DE3479398T DE3479398D1 DE 3479398 D1 DE3479398 D1 DE 3479398D1 DE 8484402531 T DE8484402531 T DE 8484402531T DE 3479398 T DE3479398 T DE 3479398T DE 3479398 D1 DE3479398 D1 DE 3479398D1
Authority
DE
Germany
Prior art keywords
fragments
human igg
subfragments
properties
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8484402531T
Other languages
German (de)
English (en)
Inventor
Edgardo D Carosella
Jacques Armand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Merieux SA
Original Assignee
Institut Merieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Merieux SA filed Critical Institut Merieux SA
Application granted granted Critical
Publication of DE3479398D1 publication Critical patent/DE3479398D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE8484402531T 1983-12-07 1984-12-07 Immunomodulating medicine based on fc fragments of human igg Expired DE3479398D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8319568A FR2556219B1 (fr) 1983-12-07 1983-12-07 Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines

Publications (1)

Publication Number Publication Date
DE3479398D1 true DE3479398D1 (en) 1989-09-21

Family

ID=9294941

Family Applications (3)

Application Number Title Priority Date Filing Date
DE8484402531T Expired DE3479398D1 (en) 1983-12-07 1984-12-07 Immunomodulating medicine based on fc fragments of human igg
DE198484402531T Pending DE147283T1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel basiert auf fe fragmenten menschlichen iggs.
DE19843444765 Ceased DE3444765A1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE198484402531T Pending DE147283T1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel basiert auf fe fragmenten menschlichen iggs.
DE19843444765 Ceased DE3444765A1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel

Country Status (7)

Country Link
US (1) US4719107A (enExample)
EP (1) EP0147283B1 (enExample)
JP (1) JPS60185726A (enExample)
AT (1) ATE45498T1 (enExample)
CA (1) CA1229791A (enExample)
DE (3) DE3479398D1 (enExample)
FR (1) FR2556219B1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US4925920A (en) * 1987-05-29 1990-05-15 Brigham And Women's Hospital Immunosuppressive polypeptides
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
GB9009106D0 (en) * 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
US5230887A (en) * 1990-07-11 1993-07-27 Immune Network Research Ltd. Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
CA2525917C (en) * 2003-05-16 2017-07-04 Mayo Foundation For Medical Education & Research Compositions and methods including a recombinant human mab that promotes cns remyelination
ATE501173T1 (de) * 2003-12-04 2011-03-15 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2006312148B2 (en) * 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2007235413B2 (en) * 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2423220B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2011517960A (ja) * 2008-04-22 2011-06-23 ザ ロックフェラー ユニバーシティー 抗炎症化合物の識別方法
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2222083B1 (enExample) * 1973-03-22 1976-05-14 Fontaine Michel
FR2267115B1 (enExample) * 1974-04-12 1977-11-10 Merieux Inst
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
DE2853453A1 (de) * 1978-12-11 1980-06-19 Behringwerke Ag Mittel zur therapie von immunkomplexerkrankungen
JPS5821623A (ja) * 1981-07-28 1983-02-08 Tetsuzo Sugizaki 抗原抗体複合体沈着疾患治療剤
JPS5821624A (ja) * 1982-04-06 1983-02-08 Tetsuzo Sugizaki 慢性関節リウマチの治療剤
EP0091760B1 (en) * 1982-04-09 1986-07-02 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Anti immune complex antibody and preparation thereof
US4465670A (en) * 1982-07-23 1984-08-14 Dainippon Pharmaceutical Co., Ltd. Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor

Also Published As

Publication number Publication date
US4719107A (en) 1988-01-12
JPH0586378B2 (enExample) 1993-12-10
FR2556219A1 (fr) 1985-06-14
CA1229791A (fr) 1987-12-01
DE147283T1 (de) 1986-04-10
EP0147283A3 (en) 1985-08-14
DE3444765A1 (de) 1985-06-20
FR2556219B1 (fr) 1987-06-26
JPS60185726A (ja) 1985-09-21
ATE45498T1 (de) 1989-09-15
EP0147283A2 (fr) 1985-07-03
EP0147283B1 (fr) 1989-08-16

Similar Documents

Publication Publication Date Title
EP0147283A3 (en) Immunomodulating medicine based on fe fragments of human igg
Low et al. Chemical characterization of thymosin beta 4.
HU891841D0 (en) Process for preparation of amino-acid-n-carboxy-anhydrides protected with urethane group
AU601765B2 (en) Polypeptide useful for the alleviation, treatment and diagnosis of autoimmune diseases, especially arthritic conditions etc.,
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
IT8223795A0 (it) Gamma), relativi veicoli di polipeptidi contenenti la sequenza espressione, loro procedimento di degli amminoacidi dell'interferone preparazione, composizioni umano immune (interferone umano farmaceutiche contenenti tali polipeptidi.
EP1440980A3 (en) Peptide analogs of human myelin basic protein
PT76831B (en) Process for preparing teichomycin a2 pure single factors 1,2,3,4 and 5 and of pharmaceutical compositions containing the same
GR3029791T3 (en) Improved immunogenic compositions against human gastrin 17
IL75637A0 (en) Thymopentin analogs and pharmaceutical compositions containing them
EP0334165A3 (en) Monoclonal antibodies
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
AU566133B2 (en) New polypeptide from thymus glands
KR100295606B1 (enExample)
EP0131836A3 (en) Alkylated fab or fc fragments of human igg, process for their preparation and pharmaceutical compositions
GR852541B (enExample)
GB8414354D0 (en) Purifying protein
Schmid et al. The amino acid sequences of two large glycopeptides derived from the carbohydrate-carrying region of α1-acid glycoprotein
AU7873191A (en) Peptide analogs to proteins of the immunoglobulin superfamily
PT82554A (en) Process for the preparation of (2,4,5-cis)dioxane and compositions therewith
IL106065A0 (en) Synthetic peptides for the treatment of myasthenia gravis and compositions comprising them
DE3361591D1 (en) Polypeptides with an antagonistic activity on substance p, process for their preparation, their use and process for the purification of polypeptides
AU1464488A (en) Human rhinovirus peptides
Götze et al. The induction of macrophage spreading by factor B of the properdin system
Diezel et al. Effect of splenopentin (SP-5) on the antibody formation in immunosuppressed mice

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee